ClinicalTrials.gg
CompletedNCT02566993ATLANTISUpdated Oct 28, 2021Results posted

Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer

A Phase 3 interventional study of Lurbinectedin (PM01183) and Doxorubicin (DOX) in Small-cell Lung Cancer, sponsored by PharmaMar. Completed at 160 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-10-28.

Sponsored by PharmaMar · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
613
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing PM 01183 in Small Cell Lung Carcinoma — 9 open to participants now, 11 under way, 3 of them phase 3. PM 01183 · Small Cell Lung Carcinoma.

Enrollment
4th of 16
613 · median 69
Started
2016
the only one that year
Phase 3
5 of 16
2 open now
Registered
2nd of 16
by date
Lead sponsor
3 of 16
PharmaMar

Among the 16 studies testing PM 01183 in Small Cell Lung Carcinoma, this one is the 4th largest by enrollment, is the only one that started in 2016, is one of 5 in phase 3, and was the 2nd registered.

Small Cell Lung Carcinoma

1,301 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

9 of the 16 studies testing PM 01183 in Small Cell Lung Carcinoma are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About PM 01183

PM 01183: first FDA approval 2020 (ZEPZELCA), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 175 (66%) set no upper age limit and 66 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing PM 01183 in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

Phase III randomized clinical trial of lurbinectedin (PM01183)/doxorubicin (DOX) versus cyclophosphamide (CTX), doxorubicin (DOX) and vincristine (VCR) (CAV) or topotecan as treatment in patients with small-cell lung cancer (SCLC) who failed one prior platinum-containing line.

Read the detailed description

Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate and compare the activity and safety of an experimental arm consisting of PM01183/DOX combination followed by PM01183 alone, if applicable vs. best Investigator's choice between CAV or topotecan as a control arm, in SCLC patients who failed one prior platinum-containing line but no more than one prior chemotherapy-containing line.

03

Conditions studied

  • Small-cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntary written
  2. Adult patients ≥ 18 years
  3. or cytologically confirmed diagnosis of limited or extensive stage SCLC which failed one prior platinum-containing regimen and with a chemotherapy-free interval (CTFI, time from the last dose of chemotherapy to the occurrence of progressive disease) ≥ 30 days. Small-cell carcinoma of unknown primary site with or without neuroendocrine features confirmed in histology test(s) performed on lesion(s) are eligible, if Ki-67/MIB-1 is expressed in >50% of tumor cells.
  4. Performance Status (ECOG PS) ≤ 2.
  5. Adequate hematological, renal, metabolic and hepatic function within 7-10 days prior to randomization
  6. At least three weeks since last prior anticancer treatment and adequate recovery from prior treatment toxicity
  7. Prior radiotherapy (RT): At least four weeks since completion of whole-brain irradiation, at least two weeks since completion of prophylactic cranial irradiation, and to any other site.
  8. Evidence of non-childbearing status for women of (WOCBP). WOCBP must agree to use a highly effective measure up to six weeks after treatment discontinuation. Fertile male patients with WOCBP partners should use condoms during treatment and for four months following the last medicinal product dose.

Exclusion criteria

Exclusion Criteria:

  1. More than one prior chemotherapy-containing line(re-challenge with the same initial regimen is not allowed)
  2. Patients who never received platinum-containing regimen for Small-cell Lung Cancer (SCLC)
  3. Prior treatment with PM01183, topotecan or anthracyclines.
  4. Limited-stage patients who are candidates for local or regional therapy
  5. Impending need for palliative RT or surgery for pathological fractures and/or for medullary compression within four weeks prior to randomization.
  6. Symptomatic or progressing or requiring Central Nervous System (CNS) involvement disease at least four weeks prior to randomization
  7. Concomitant diseases/conditions:

    Angina, myocardial infarction, congestive heart failure or valvular heart disease, arrhythmia, immunodeficiency (including known seropositive), ongoing or treatment-requiring chronic liver disease, active infection, oxygen requirement within two weeks prior to randomization, diffuse interstitial lung disease (ILD) or pulmonary fibrosis, second invasive treated with chemotherapy and/or radiotherapy, invasive fungal infections requiring systemic treatment within 12 weeks of randomization.

  8. Pregnant or breast feeding women
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
613 participants (actual)

Study arms

  • Experimental
    Experimental Arm

    Lurbinectedin (PM01183) / Doxorubicin

    Drug: Lurbinectedin (PM01183) · Drug: Doxorubicin (DOX)

  • Active comparator
    Control Arm 1

    CAV (Cyclophosphamide (CTX), Doxorubicin (DOX) and Vincristine (VCR))

    Drug: Doxorubicin (DOX) · Drug: Cyclophosphamide (CTX) · Drug: Vincristine (VCR)

  • Active comparator
    Control Arm 2

    Topotecan

    Drug: Topotecan

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).

    Time frame: Every three months up to death or study termination, a period of approximately 3.5 years

Secondary outcomes

  1. Difference in Overall Survival Between Lurbinectedin/Doxorubicin (DOX) and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 12 Months

    Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).

    Time frame: At 12 months

  2. Difference in Overall Survival Between Lurbinectedin/DOX and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 18 Months

    Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).

    Time frame: At 18 months

  3. Difference in Overall Survival Between Lurbinectedin/DOX and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 24 Months

    Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).

    Time frame: At 24 months

  4. Progression-free Survival (PFS) by Independent Review Committee

    Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.

    Time frame: Every six weeks up to progression disease, a period of approximately 3.5 years

  5. Progression-free Survival Rate at 6 Months by Independent Review Committee

    Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.

    Time frame: At 6 months

  6. Progression-free Survival Rate at 12 Months by Independent Review Committee

    Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.

    Time frame: at 12 months

  7. Best Antitumor Response by Independent Review Committee

    Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

    Time frame: Every three months up to death or study termination, a period of approximately 3.5 years

  8. Overall Response Rate by Independent Review Committee

    Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

    Time frame: Every three months up to death or study termination, a period of approximately 3.5 years

  9. Duration of Response by Independent Review Committee

    Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

    Time frame: Every three months up to death or study termination, a period of approximately 3.5 years

  10. Overall Survival in Patients With Chemotherapy-free Interval ≥ 90 Days

    Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).

    Time frame: Every three months up to death or study termination, a period of approximately 3.5 years

  11. Progression-free Survival in Patients With Chemotherapy-free Interval ≥90 Days

    Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.

    Time frame: Every six weeks up to progression disease, a period of approximately 3.5 years

  12. Best Antitumor Response in Patients With Chemotherapy-free Interval ≥ 90 Days

    Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

    Time frame: Every three months up to death or study termination, a period of approximately 3.5 years

  13. Overall Response Rate in Patients With Chemotherapy-free Interval ≥ 90 Days

    Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

    Time frame: Every three months up to death or study termination, a period of approximately 3.5 years

  14. Duration of Response in Patients With Chemotherapy-free Interval ≥ 90 Days

    Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

    Time frame: Every three months up to death or study termination, a period of approximately 3.5 years

  15. Overall Survival in Patients With Chemotherapy-free Interval < 90 Days

    Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).

    Time frame: Every three months up to death or study termination, a period of approximately 3.5 years

  16. Progression-free Survival in Patients With Chemotherapy-free Interval <90 Days

    Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.

    Time frame: Every six weeks up to progression disease, a period of approximately 3.5 years

  17. Best Antitumor Response in Patients With Chemotherapy-free Interval <90 Days

    Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

    Time frame: Every three months up to death or study termination, a period of approximately 3.5 years

  18. Overall Response Rate in Patients With Chemotherapy-free Interval <90 Days

    Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

    Time frame: Every three months up to death or study termination, a period of approximately 3.5 years

  19. Duration of Response in Patients With Chemotherapy-free Interval <90 Days

    Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

    Time frame: Every three months up to death or study termination, a period of approximately 3.5 years

  20. Overall Survival in Patients Without Central Nervous System Involvement at Baseline

    Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).

    Time frame: Every three months up to death or study termination, a period of approximately 3.5 years

  21. Progression-free Survival in Patients Without Central Nervous System Involvement at Baseline

    Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.

    Time frame: Every six weeks up to progression disease, a period of approximately 3.5 years

  22. Best Antitumor Response in Patients Without Central Nervous System Involvement at Baseline

    Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

    Time frame: Every three months up to death or study termination, a period of approximately 3.5 years

  23. Overall Response Rate in Patients Without Central Nervous System Involvement at Baseline

    Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

    Time frame: Every three months up to death or study termination, a period of approximately 3.5 years

  24. Duration of Response in Patients Without Central Nervous System Involvement at Baseline

    Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

    Time frame: Every three months up to death or study termination, a period of approximately 3.5 years

  25. Overall Survival in Patients With Central Nervous System Involvement at Baseline

    Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).

    Time frame: Every three months up to death or study termination, a period of approximately 3.5 years

  26. Progression-free Survival in Patients With Central Nervous System Involvement at Baseline

    Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.

    Time frame: Every six weeks up to progression disease, a period of approximately 3.5 years

  27. Best Antitumor Response in Patients With Central Nervous System Involvement at Baseline

    Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

    Time frame: Every three months up to death or study termination, a period of approximately 3.5 years

  28. Overall Response Rate in Patients With Central Nervous System Involvement at Baseline

    Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

    Time frame: Every three months up to death or study termination, a period of approximately 3.5 years

  29. Duration of Response in Patients With Central Nervous System Involvement at Baseline

    Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

    Time frame: Every three months up to death or study termination, a period of approximately 3.5 years

07

Results

Posted Oct 28, 2021

Participant flow

The first randomization took place on 30 August 2016 and the first study treatment was administered on 25 October 2016. The cutoff date for results presented in this Clinical Study Report was 24 February 2020. A total of 919 patients were screened; 613 of these 919 patients were randomized at a 1:1 ratio to receive any of the study treatments at 135 investigational sites from 20 countries.

Participant flow — Overall Study
MilestoneLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Started307306
Completed00
Not completed307306
Withdrew: Randomized but not treated516
Withdrew: Progressive disease213152
Withdrew: Withdrawal by subject1228
Withdrew: Death1723
Withdrew: Physician decision1017
Withdrew: Study drug-related adverse event2041
Withdrew: Non study drug-related adverse event99
Withdrew: Symptomatic deterioration916
Withdrew: End of study due to events required for os analysis according to study protocol had been reached91
Withdrew: Sponsor's decision after incorrect treatment at site11
Withdrew: Screening failure20
Withdrew: Lost to follow-up01
Withdrew: Symptomatic deterioration, progression disease, and a decision by the investigator01

Outcome measures

PrimaryOverall Survival (OS)

Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).

Time frame:
Every three months up to death or study termination, a period of approximately 3.5 years
Reported as:
Median · months
Overall Survival (OS)
monthsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Overall Survival (OS)8.6 (7.1 to 9.4)7.6 (6.6 to 8.2)
Statistical analysis
  • Lurbinectedin/Doxorubicin vs Topotecan or Cyclophosphamide/Doxorubicin/Vincristine · Log Rank · p = 0.9029 · Hazard ratio (hr): 0.967 · 95% CI 0.815 to 1.148Stratified log-rank test
SecondaryDifference in Overall Survival Between Lurbinectedin/Doxorubicin (DOX) and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 12 Months

Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).

Time frame:
At 12 months
Reported as:
Number · percentage of participants
Difference in Overall Survival Between Lurbinectedin/Doxorubicin (DOX) and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 12 Months
percentage of participantsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Difference in Overall Survival Between Lurbinectedin/Doxorubicin (DOX) and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 12 Months29.6 (22.8 to 36.3)24.4 (17.9 to 31.0)
Statistical analysis
  • Lurbinectedin/Doxorubicin vs Topotecan or Cyclophosphamide/Doxorubicin/Vincristine · Normal test · p = 0.2826
SecondaryDifference in Overall Survival Between Lurbinectedin/DOX and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 18 Months

Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).

Time frame:
At 18 months
Reported as:
Number · percentage of participants
Difference in Overall Survival Between Lurbinectedin/DOX and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 18 Months
percentage of participantsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Difference in Overall Survival Between Lurbinectedin/DOX and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 18 Months13.9 (8.8 to 19.1)15.9 (10.3 to 21.4)
Statistical analysis
  • Lurbinectedin/Doxorubicin vs Topotecan or Cyclophosphamide/Doxorubicin/Vincristine · Normal test · p = 0.6216
SecondaryDifference in Overall Survival Between Lurbinectedin/DOX and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 24 Months

Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).

Time frame:
At 24 months
Reported as:
Number · percentage of participants
Difference in Overall Survival Between Lurbinectedin/DOX and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 24 Months
percentage of participantsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Difference in Overall Survival Between Lurbinectedin/DOX and CAV in Patients With CAV as Best Investigator's Choice: Overall Survival Rate at 24 Months8.6 (4.1 to 13.1)8.7 (4.1 to 13.4)
Statistical analysis
  • Lurbinectedin/Doxorubicin vs Topotecan or Cyclophosphamide/Doxorubicin/Vincristine · Normal test · p = 0.9708
SecondaryProgression-free Survival (PFS) by Independent Review Committee

Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.

Time frame:
Every six weeks up to progression disease, a period of approximately 3.5 years
Reported as:
Median · months
Progression-free Survival (PFS) by Independent Review Committee
monthsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Progression-free Survival (PFS) by Independent Review Committee4.0 (2.8 to 4.2)4.0 (3.0 to 4.1)
Statistical analysis
  • Lurbinectedin/Doxorubicin vs Topotecan or Cyclophosphamide/Doxorubicin/Vincristine · Log Rank · p = 0.3257 · Hazard ratio (hr): 0.831 · 95% CI 0.693 to 0.996Stratified log-rank test
SecondaryProgression-free Survival Rate at 6 Months by Independent Review Committee

Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.

Time frame:
At 6 months
Reported as:
Number · percentage of participants
Progression-free Survival Rate at 6 Months by Independent Review Committee
percentage of participantsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Progression-free Survival Rate at 6 Months by Independent Review Committee31.3 (25.7 to 36.8)24.4 (18.9 to 29.9)
Statistical analysis
  • Lurbinectedin/Doxorubicin vs Topotecan or Cyclophosphamide/Doxorubicin/Vincristine · Normal test · p = 0.0851
SecondaryProgression-free Survival Rate at 12 Months by Independent Review Committee

Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.

Time frame:
at 12 months
Reported as:
Number · percentage of participants
Progression-free Survival Rate at 12 Months by Independent Review Committee
percentage of participantsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Progression-free Survival Rate at 12 Months by Independent Review Committee10.8 (6.7 to 14.9)4.4 (1.4 to 7.4)
Statistical analysis
  • Lurbinectedin/Doxorubicin vs Topotecan or Cyclophosphamide/Doxorubicin/Vincristine · Normal test · p = 0.0129
SecondaryBest Antitumor Response by Independent Review Committee

Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

Time frame:
Every three months up to death or study termination, a period of approximately 3.5 years
Reported as:
Count of participants · Participants
Best Antitumor Response by Independent Review Committee
ParticipantsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Complete response84
Partial response8987
Stable disease111116
Progressive disease7452
Unknown2547
SecondaryOverall Response Rate by Independent Review Committee

Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

Time frame:
Every three months up to death or study termination, a period of approximately 3.5 years
Reported as:
Number · percentage of participants
Overall Response Rate by Independent Review Committee
percentage of participantsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Overall Response Rate by Independent Review Committee31.6 (26.4 to 37.1)29.7 (24.7 to 35.2)
Statistical analysis
  • Lurbinectedin/Doxorubicin vs Topotecan or Cyclophosphamide/Doxorubicin/Vincristine · Binomial test · p = 0.6616
SecondaryDuration of Response by Independent Review Committee

Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

Time frame:
Every three months up to death or study termination, a period of approximately 3.5 years
Reported as:
Median · months
Duration of Response by Independent Review Committee
monthsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Duration of Response by Independent Review Committee5.7 (4.1 to 7.1)3.8 (2.8 to 4.3)
Statistical analysis
  • Lurbinectedin/Doxorubicin vs Topotecan or Cyclophosphamide/Doxorubicin/Vincristine · Log Rank · p = 0.0012 · Hazard ratio (hr): 0.581 · 95% CI 0.416 to 0.812
SecondaryOverall Survival in Patients With Chemotherapy-free Interval ≥ 90 Days

Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).

Time frame:
Every three months up to death or study termination, a period of approximately 3.5 years
Reported as:
Median · months
Overall Survival in Patients With Chemotherapy-free Interval ≥ 90 Days
monthsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Overall Survival in Patients With Chemotherapy-free Interval ≥ 90 Days10.3 (9.0 to 11.8)8.7 (7.8 to 9.8)
Statistical analysis
  • Lurbinectedin/Doxorubicin vs Topotecan or Cyclophosphamide/Doxorubicin/Vincristine · Hazard ratio (hr): 0.921 · 95% CI 0.744 to 1.140
SecondaryProgression-free Survival in Patients With Chemotherapy-free Interval ≥90 Days

Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.

Time frame:
Every six weeks up to progression disease, a period of approximately 3.5 years
Reported as:
Median · months
Progression-free Survival in Patients With Chemotherapy-free Interval ≥90 Days
monthsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Progression-free Survival in Patients With Chemotherapy-free Interval ≥90 Days4.8 (4.1 to 5.6)4.4 (4.0 to 5.3)
Statistical analysis
  • Lurbinectedin/Doxorubicin vs Topotecan or Cyclophosphamide/Doxorubicin/Vincristine · Hazard ratio (hr): 0.688 · 95% CI 0.549 to 0.863
SecondaryBest Antitumor Response in Patients With Chemotherapy-free Interval ≥ 90 Days

Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

Time frame:
Every three months up to death or study termination, a period of approximately 3.5 years
Reported as:
Count of participants · Participants
Best Antitumor Response in Patients With Chemotherapy-free Interval ≥ 90 Days
ParticipantsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Complete response84
Partial response6968
Stable disease8573
Progression disease3235
Unknown1425
SecondaryOverall Response Rate in Patients With Chemotherapy-free Interval ≥ 90 Days

Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

Time frame:
Every three months up to death or study termination, a period of approximately 3.5 years
Reported as:
Number · percentage of participants
Overall Response Rate in Patients With Chemotherapy-free Interval ≥ 90 Days
percentage of participantsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Overall Response Rate in Patients With Chemotherapy-free Interval ≥ 90 Days37.0 (30.4 to 44.0)35.1 (28.6 to 42.1)
Statistical analysis
  • Lurbinectedin/Doxorubicin vs Topotecan or Cyclophosphamide/Doxorubicin/Vincristine · Hazard ratio (hr): 0.921 · 95% CI 0.616 to 1.376
SecondaryDuration of Response in Patients With Chemotherapy-free Interval ≥ 90 Days

Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

Time frame:
Every three months up to death or study termination, a period of approximately 3.5 years
Reported as:
Median · months
Duration of Response in Patients With Chemotherapy-free Interval ≥ 90 Days
monthsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Duration of Response in Patients With Chemotherapy-free Interval ≥ 90 Days6.9 (4.1 to 8.3)4.0 (3.0 to 4.8)
Statistical analysis
  • Lurbinectedin/Doxorubicin vs Topotecan or Cyclophosphamide/Doxorubicin/Vincristine · Hazard ratio (hr): 0.504 · 95% CI 0.346 to 0.736
SecondaryOverall Survival in Patients With Chemotherapy-free Interval < 90 Days

Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).

Time frame:
Every three months up to death or study termination, a period of approximately 3.5 years
Reported as:
Median · months
Overall Survival in Patients With Chemotherapy-free Interval < 90 Days
monthsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Overall Survival in Patients With Chemotherapy-free Interval < 90 Days5.7 (4.1 to 6.7)5.3 (4.2 to 6.1)
Statistical analysis
  • Lurbinectedin/Doxorubicin vs Topotecan or Cyclophosphamide/Doxorubicin/Vincristine · Hazard ratio (hr): 1.122 · 95% CI 0.840 to 1.500
SecondaryProgression-free Survival in Patients With Chemotherapy-free Interval <90 Days

Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.

Time frame:
Every six weeks up to progression disease, a period of approximately 3.5 years
Reported as:
Median · months
Progression-free Survival in Patients With Chemotherapy-free Interval <90 Days
monthsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Progression-free Survival in Patients With Chemotherapy-free Interval <90 Days1.6 (1.4 to 2.7)2.8 (2.5 to 3.0)
Statistical analysis
  • Lurbinectedin/Doxorubicin vs Topotecan or Cyclophosphamide/Doxorubicin/Vincristine · Hazard ratio (hr): 1.306 · 95% CI 0.955 to 1.786
SecondaryBest Antitumor Response in Patients With Chemotherapy-free Interval <90 Days

Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

Time frame:
Every three months up to death or study termination, a period of approximately 3.5 years
Reported as:
Count of participants · Participants
Best Antitumor Response in Patients With Chemotherapy-free Interval <90 Days
ParticipantsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Partial response2019
Stable disease2643
Progression disease4217
Unknown1122
SecondaryOverall Response Rate in Patients With Chemotherapy-free Interval <90 Days

Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

Time frame:
Every three months up to death or study termination, a period of approximately 3.5 years
Reported as:
Number · percentage of participants
Overall Response Rate in Patients With Chemotherapy-free Interval <90 Days
percentage of participantsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Overall Response Rate in Patients With Chemotherapy-free Interval <90 Days20.2 (12.8 to 29.5)18.8 (11.7 to 27.8)
Statistical analysis
  • Lurbinectedin/Doxorubicin vs Topotecan or Cyclophosphamide/Doxorubicin/Vincristine · Hazard ratio (hr): 0.915 · 95% CI 0.455 to 1.843
SecondaryDuration of Response in Patients With Chemotherapy-free Interval <90 Days

Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

Time frame:
Every three months up to death or study termination, a period of approximately 3.5 years
Reported as:
Median · months
Duration of Response in Patients With Chemotherapy-free Interval <90 Days
monthsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Duration of Response in Patients With Chemotherapy-free Interval <90 Days3.0 (1.4 to 4.5)2.8 (1.4 to 4.1)
Statistical analysis
  • Lurbinectedin/Doxorubicin vs Topotecan or Cyclophosphamide/Doxorubicin/Vincristine · Hazard ratio (hr): 1.092 · 95% CI 0.506 to 2.360
SecondaryOverall Survival in Patients Without Central Nervous System Involvement at Baseline

Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).

Time frame:
Every three months up to death or study termination, a period of approximately 3.5 years
Reported as:
Median · months
Overall Survival in Patients Without Central Nervous System Involvement at Baseline
monthsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Overall Survival in Patients Without Central Nervous System Involvement at Baseline9.1 (8.1 to 10.2)7.7 (6.7 to 8.6)
Statistical analysis
  • Lurbinectedin/Doxorubicin vs Topotecan or Cyclophosphamide/Doxorubicin/Vincristine · Hazard ratio (hr): 0.923 · 95% CI 0.765 to 1.113
SecondaryProgression-free Survival in Patients Without Central Nervous System Involvement at Baseline

Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.

Time frame:
Every six weeks up to progression disease, a period of approximately 3.5 years
Reported as:
Median · months
Progression-free Survival in Patients Without Central Nervous System Involvement at Baseline
monthsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Progression-free Survival in Patients Without Central Nervous System Involvement at Baseline4.2 (3.7 to 4.8)4.1 (3.1 to 4.3)
Statistical analysis
  • Lurbinectedin/Doxorubicin vs Topotecan or Cyclophosphamide/Doxorubicin/Vincristine · Hazard ratio (hr): 0.788 · 95% CI 0.645 to 0.961
SecondaryBest Antitumor Response in Patients Without Central Nervous System Involvement at Baseline

Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

Time frame:
Every three months up to death or study termination, a period of approximately 3.5 years
Reported as:
Count of participants · Participants
Best Antitumor Response in Patients Without Central Nervous System Involvement at Baseline
ParticipantsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Complete response73
Partial response7976
Stable disease101100
Progression disease5540
Unknown1938
SecondaryOverall Response Rate in Patients Without Central Nervous System Involvement at Baseline

Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

Time frame:
Every three months up to death or study termination, a period of approximately 3.5 years
Reported as:
Number · percentage of participants
Overall Response Rate in Patients Without Central Nervous System Involvement at Baseline
percentage of participantsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Overall Response Rate in Patients Without Central Nervous System Involvement at Baseline33.0 (27.3 to 39.0)30.7 (25.2 to 36.8)
Statistical analysis
  • Lurbinectedin/Doxorubicin vs Topotecan or Cyclophosphamide/Doxorubicin/Vincristine · Hazard ratio (hr): 0.903 · 95% CI 0.624 to 1.307
SecondaryDuration of Response in Patients Without Central Nervous System Involvement at Baseline

Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

Time frame:
Every three months up to death or study termination, a period of approximately 3.5 years
Reported as:
Median · months
Duration of Response in Patients Without Central Nervous System Involvement at Baseline
monthsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Duration of Response in Patients Without Central Nervous System Involvement at Baseline5.7 (4.1 to 7.3)4.0 (3.0 to 4.9)
Statistical analysis
  • Lurbinectedin/Doxorubicin vs Topotecan or Cyclophosphamide/Doxorubicin/Vincristine · Hazard ratio (hr): 0.560 · 95% CI 0.392 to 0.799
SecondaryOverall Survival in Patients With Central Nervous System Involvement at Baseline

Overall survival (OS) will be calculated from the date of randomization to the date of death (death event) or last contact(in this case, survival will be censored on that date).

Time frame:
Every three months up to death or study termination, a period of approximately 3.5 years
Reported as:
Median · months
Overall Survival in Patients With Central Nervous System Involvement at Baseline
monthsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Overall Survival in Patients With Central Nervous System Involvement at Baseline4.6 (3.1 to 6.1)6.6 (4.0 to 8.8)
Statistical analysis
  • Lurbinectedin/Doxorubicin vs Topotecan or Cyclophosphamide/Doxorubicin/Vincristine · Hazard ratio (hr): 1.291 · 95% CI 0.838 to 1.990
SecondaryProgression-free Survival in Patients With Central Nervous System Involvement at Baseline

Progression-free survival (PFS) is defined as the time from the date of randomization to the date of documented progression per RECIST v.1.1 or death (regardless of the cause of death). If the patient receives further antitumor therapy or is lost to follow-up before PD, PFS will be censored at the date of last tumor assessment before the date of subsequent antitumor therapy.

Time frame:
Every six weeks up to progression disease, a period of approximately 3.5 years
Reported as:
Median · months
Progression-free Survival in Patients With Central Nervous System Involvement at Baseline
monthsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Progression-free Survival in Patients With Central Nervous System Involvement at Baseline1.9 (1.4 to 2.7)2.8 (1.4 to 3.8)
Statistical analysis
  • Lurbinectedin/Doxorubicin vs Topotecan or Cyclophosphamide/Doxorubicin/Vincristine · Hazard ratio (hr): 1.290 · 95% CI 0.824 to 2.019
SecondaryBest Antitumor Response in Patients With Central Nervous System Involvement at Baseline

Best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

Time frame:
Every three months up to death or study termination, a period of approximately 3.5 years
Reported as:
Count of participants · Participants
Best Antitumor Response in Patients With Central Nervous System Involvement at Baseline
ParticipantsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Complete response11
Partial response1011
Stable disease1016
Progression disease1912
Unknown69
SecondaryOverall Response Rate in Patients With Central Nervous System Involvement at Baseline

Overall response rate is defined as the proportion of patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

Time frame:
Every three months up to death or study termination, a period of approximately 3.5 years
Reported as:
Number · percentage of participants
Overall Response Rate in Patients With Central Nervous System Involvement at Baseline
percentage of participantsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Overall Response Rate in Patients With Central Nervous System Involvement at Baseline23.9 (12.6 to 38.8)24.5 (13.3 to 38.9)
Statistical analysis
  • Lurbinectedin/Doxorubicin vs Topotecan or Cyclophosphamide/Doxorubicin/Vincristine · Hazard ratio (hr): 1.032 · 95% CI 0.403 to 2.641
SecondaryDuration of Response in Patients With Central Nervous System Involvement at Baseline

Duration of Response is defined as the time that patients who have a partial or complete response in the best antitumor response. The best antitumor response will be the best response obtained in any evaluation according to RECIST v.1.1. CR, complete response: disappearance of all lesions; PD, disease progression: ≥10% increase in target lesion size and does not meet tumor density criteria of PR density; PR, partial response: ≥10% decrease in target lesion size or ≥15% decrease in tumor density; SD, stable disease: none of the CR, PR, or PD criteria met; UK,unknown

Time frame:
Every three months up to death or study termination, a period of approximately 3.5 years
Reported as:
Median · months
Duration of Response in Patients With Central Nervous System Involvement at Baseline
monthsLurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/Vincristine
Duration of Response in Patients With Central Nervous System Involvement at Baseline1.5 (0.1 to NA)2.7 (1.3 to 4.0)
Statistical analysis
  • Lurbinectedin/Doxorubicin vs Topotecan or Cyclophosphamide/Doxorubicin/Vincristine · Hazard ratio (hr): 1.013 · 95% CI 0.373 to 2.750

Adverse events

Collected over Patients were assessed through study completion, approximately 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lurbinectedin/Doxorubicin264/303 (87.1%)126/303 (41.6%)292/303 (96.4%)
Topotecan100/121 (82.6%)66/121 (54.5%)120/121 (99.2%)
Cyclophosphamide/Doxorubicin/Vincristine148/168 (88.1%)75/168 (44.6%)148/168 (88.1%)
Most frequent serious events
Showing 10 of 133
Most frequent serious events
EventLurbinectedin/DoxorubicinTopotecanCyclophosphamide/Doxorubicin/Vincristine
ThrombocytopeniaBlood and lymphatic system disorders9/30315/1214/168
AnaemiaBlood and lymphatic system disorders10/30313/1219/168
Febrile neutropeniaBlood and lymphatic system disorders12/3037/12117/168
NeutropeniaBlood and lymphatic system disorders4/3039/12112/168
PneumoniaInfections and infestations14/3035/1217/168
FatigueGeneral disorders4/3035/1212/168
Lower respiratory tract infectionInfections and infestations5/3035/1216/168
General physical health deteriorationGeneral disorders7/3034/1215/168
SepsisInfections and infestations3/3034/1212/168
Septic shockInfections and infestations0/3034/1214/168
Most frequent other events
Showing 10 of 39
Most frequent other events
EventLurbinectedin/DoxorubicinTopotecanCyclophosphamide/Doxorubicin/Vincristine
AnaemiaBlood and lymphatic system disorders121/30384/12189/168
NeutropeniaBlood and lymphatic system disorders101/30374/121107/168
ThrombocytopeniaBlood and lymphatic system disorders70/30371/12161/168
FatigueGeneral disorders164/30364/12179/168
NauseaGastrointestinal disorders123/30333/12155/168
Decreased appetiteMetabolism and nutrition disorders85/30320/12140/168
LeukopeniaBlood and lymphatic system disorders28/30332/12146/168
ConstipationGastrointestinal disorders59/30330/12125/168
VomitingGastrointestinal disorders72/30315/12133/168
Weight decreasedInvestigations64/30314/12124/168

Baseline characteristics

Age, Continuous
Age, Continuous(years)Lurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/VincristineTotal
Median63.0 (19 to 83)63.0 (37 to 82)63 (19 to 83)
Age, Customized
Age, Customized(Participants)Lurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/VincristineTotal
18-49 years161329
50-65 years161166327
>65 years130127257
Sex: Female, Male
Sex: Female, Male(Participants)Lurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/VincristineTotal
Female131133264
Male176173349
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Lurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/VincristineTotal
White266265531
Black or African American112
Asian011
Other224
Not available383775
Region of Enrollment
Region of Enrollment(Participants)Lurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/VincristineTotal
Argentina347
Romania201939
Hungary232346
United States323062
Czechia459
United Kingdom101121
Portugal10515
Spain6263125
Greece121325
Lebanon8917
Canada10717
Austria538
Netherlands9918
Belgium91221
Brazil131528
Poland7613
Italy212041
Bulgaria5611
France111223
Germany333467
Weight
Weight(Kg)Lurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/VincristineTotal
Median73.0 (40 to 143)74.0 (38 to 158)73.4 (37.9 to 158)
Height
Height(cm)Lurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/VincristineTotal
Median168 (145 to 196)168 (146 to 191)168 (145 to 196)
Body surface area
Body surface area(m^2)Lurbinectedin/DoxorubicinTopotecan or Cyclophosphamide/Doxorubicin/VincristineTotal
Median1.8 (1.4 to 2.5)1.8 (1.3 to 2.8)1.8 (1.3 to 2.8)

20 further baseline measures are reported on the registry.

08

Study locations

160 sites
  • Alabama Oncology
    Birmingham, Alabama 35243, United States
  • Ironwood Physicians P.C. dba Ironwood Cancer & Research Centers
    Chandler, Arizona 85224, United States
  • St Jude Hospital Yorba Linda dba St Joseph Heritage Healthcare
    Fullerton, California 92835, United States
  • Loma Linda University Medica! Center
    Loma Linda, California 92354, United States
  • Innovative Clinical Research Institute (ICRI)
    Whittier, California 90603, United States
  • Boca Raton Regional Hospital Lynn Cancer Institute
    Boca Raton, Florida 33486, United States
  • Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center
    Fort Lauderdale, Florida 33308, United States
  • H. Lee Moffitt Cancer Center & Research Institute
    Tampa, Florida 33612, United States
  • Joliet Oncology-Hematology Associates, Ltd.
    Joliet, Illinois 60435, United States
  • Healthcare Research Network III, LLC
    Tinley Park, Illinois 60487, United States
  • Carle Cancer Center
    Urbana, Illinois 61801, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40202, United States
  • Montgomery Cancer Center
    Mount Sterling, Kentucky 40353, United States
  • East Jefferson Hematology-Oncology Metairie Physicians Services, Inc
    Metairie, Louisiana 70006, United States
  • Anne Arundel Medical Center Oncology and Hematology
    Annapolis, Maryland 21401, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • QUEST Research Institute
    Royal Oak, Michigan 48073, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89169, United States
  • Dartmouth-Hitchcock Medical Center/Mary Hitchcock Memorial Hospital
    Lebanon, New Hampshire 03756, United States
  • Summit Medical Group, P.A.
    Florham Park, New Jersey 07932, United States
  • FirstHealth Outpatient Cancer Center
    Pinehurst, North Carolina 28374, United States
  • Gabrail Cancer Center Research
    Canton, Ohio 44718, United States
  • Oklahoma Cancer Specialists and Research Institute, LLC
    Tulsa, Oklahoma 74146, United States
  • Associates in Hematology and Oncology, P.C.
    Upland, Pennsylvania 19013, United States
  • The Center for Cancer and Blood Disorders
    Fort Worth, Texas 76104, United States
  • Tyler Hematology-Oncology PA
    Tyler, Texas 75701, United States
  • Medical Oncology Associates PS (dba Summit Cancer Centers)
    Spokane, Washington 99208, United States
  • MultiCare Institute for Research & Innovation
    Tacoma, Washington 98405, United States
  • Froedtert Hospital & the Medical College of Wisconsin
    Milwaukee, Wisconsin 53226, United States
  • Instituto Médico Especializado Alexander Fleming
    C.a.b.a., Buenos Aires C1426ANZ, Argentina
  • Centro para la Atención Integral del Paciente Oncológico (CAIPO)
    San Miguel de Tucumán, Tucumán T4000GTB, Argentina
  • Instituto Oncológico de Córdoba (IONC)
    Córdoba, X5000HLX, Argentina
  • CORI - Centro Oncológico Riojano Integral
    La Rioja, F5300COE, Argentina
  • ISIS Centro Especializado de Luce S.A.
    Santa Fe, S3000FFU, Argentina
  • Universitätsklinik für Innere Medizin III der PMU
    Salzburg, 5020, Austria
  • Medizinische Universität Wien / AKH Wien, Universitätsklinik für Innere Medizin I, Abteilung für klinische Onkologie
    Wien, 1090, Austria
  • AZ Maria Middelares
    Gent, 9000, Belgium
  • Clinique André Renard
    Herstal, 4040, Belgium
  • CHR de la citadelle
    Liege, 4000, Belgium
  • CHU de Liege - Sart Tilman
    Liege, 4000, Belgium
  • CHU Ambroise Paré
    Mons, 7000, Belgium
  • AZ Delta Campus Wilgenstraat
    Roeselare, 8800, Belgium
  • Nucleo de Oncologia da Bahia
    Salvador, BA 40170-110, Brazil
  • lOP- Instituto de oncologia do paraná
    Curitiba, Paraná 80530-010, Brazil
  • Coordenação de Pesquisa Clínica / Instituto Nacional de Câncer
    Rio de Janeiro, RJ 20231-092, Brazil
  • Instituto COl de Pesquisa, Educação e Gestão
    Rio de Janeiro, RJ 22793-080, Brazil
  • Associação Hospital de Caridade de Ijuí
    Ijui, RS 98700-000, Brazil
  • lrmandade da Santa Casa de Misericórdia de Porto Alegre
    Porto Alegre, RS 90020-090, Brazil
  • Hospital São Lucas da PUCRS
    Porto Alegre, RS 90610-000, Brazil
  • Hospital de clínicas de Porto alegre
    Pôrto Alegre, RS 90.035-903, Brazil
  • Fundação PlO XII - Hospital de Câncer de Barretos
    Barretos, São Paulo 14784-400, Brazil
  • lnstituto de Ensino e Pesquisa Säo Lucas - IEP Säo Lucas
    Sao Paulo, São Paulo 01236-030, Brazil
  • Multiprofile Hospital for Active Treatment - Uni Hospital, Panagyurishte
    Panagyurishte, 4500, Bulgaria
  • Multiprofile Hospital for Active Treatment of Women Health - "Nadezhda", Sofia; Clinic of Medical Oncology
    Sofia, 1330, Bulgaria
  • University Multiprofile Hospital for Active Treatment "Sv. Ivan Rilski", Sofia
    Sofia, 1431, Bulgaria
  • Acibadem City Clinic University Multiprofile Hospital for Active Treatment. EOOD, Sofia; Clinic of Medical Oncology
    Sofia, 1784, Bulgaria
  • Southlake Regional Health Centre - Stronach Regional Cancer Centre
    Newmarket, Ontario L3Y 2P9, Canada
  • R.S. Mc Laughlin Durham Regional Cancer Centre, Lakeridge Health
    Oshawa, Ontario L1G 2B9, Canada
  • Centre intégré de santé et de services sociaux de la Montérégie Centre
    Greenfield Park, Quebec J4V 2H1, Canada
  • Biron (Clinique René Laennec)
    Mont-Royal, Quebec H3P 3H5, Canada
  • Montreal Oncology Research Inc.
    Montreal, Quebec H1M 1B1, Canada
  • McGill University Health Centre
    Montréal, Quebec H4A 3J1, Canada
  • Vitkovicka nemocnice, a.s., Plicni oddeleni
    Ostrava, 703 84, Czechia
  • Krajska zdravotni a.s. Masarykova nemocnice o.z.
    Usti nad Labem, 401 13, Czechia
  • Institut Bergonié
    Bordeaux, 33076, France
  • Centre François Baclesse
    Caen, 14076, France
  • Centre Hospitalier Intercommunal de Créteil
    Creteil, 94010, France
  • Centre Hospitalier Lyon Sud - Service de Pneumologie
    Lyon, 69310, France
  • Hôpital Nord - Service Oncologie Multidisciplinaire et Innovations Thérapeutiques
    Marseille, 13915, France
  • Centre Antoine Lacassagne
    Nice Cedex 2, 06189, France
  • CHU de Rennes Hôpital Pontchaillou
    Rennes, 35033, France
  • Central Clinic of Bad Berka
    Bad Berka, 99437, Germany
  • Vivantes Klinikum am Urban, Hämatologie und Onkologie
    Berlin, 10967, Germany
  • Evangelische Lungenklinik Berlin
    Berlin, 13125, Germany
  • Uniklinik Freiburg, Hämatologie, Onkologie & Stammzellransplantation
    Freiburg, 79106, Germany
  • Asklepios-Fachkliniken München Gauting
    Gauting, 82131, Germany
  • Center for Pneumology and Thoracic Surgery
    Gerlingen, 70839, Germany
  • Thoraxklinik Heidelberg GmbH
    Heidelberg, 69126, Germany
  • Lungenklinik Hemer
    Hemer, 58675, Germany
  • VIDIA Christliche Kliniken Karlsruhe
    Karlsruhe, 76137, Germany
  • Katholisches Klinikum Koblenz-Montabaur, Marienhof Koblenz
    Koblenz, 56073, Germany
  • Onkologische Schwerpunktpraxis Leer-Emden
    Leer, 26789, Germany
  • Klinik Löwenstein gGmbH, Med. Klinik II Onkologie
    Löwenstein, 74245, Germany
  • Uniklinikum Mannheim, TTZ, Medizinische Fakultät Mannheim
    Mannheim, 68167, Germany
  • Johannes Wesling Klinikum Minden, Klinik für Hämatologie, Onkologie und Palliativmedizin
    Minden, 32429, Germany
  • University of Munich LMU, Dpt. of Medicine V
    Munchen, 80336, Germany
  • Städtisches Krankenhaus München Neuperlach
    Munchen, 81737, Germany
  • Klinikum Bogenhausen, Städt. Klinikum München GmbH, Klinik für Pneumologie und Pneumologische Onkologie
    Munchen, 81925, Germany
  • Klinikum Nürnberg Nord - Pneumologische Onkologie
    Nuremberg, 90419, Germany
  • Universitätsklinikum Ulm - Klinik für Innere Medizin II, Pneumologie
    Ulm, 89081, Germany
  • Medizinische Klinik I
    Wuppertal, 42283, Germany
  • University General Hospital of Heraklion - General Hospital "Venizeleio"
    Heraklion, Crete 71110, Greece
  • General Hospital of Chest Diseases of Athens "Sotiria"
    Athens, 11527, Greece
  • General Oncology Hospital of Kifissia "Agioi Anargiroi", 2nd Internal Medicine-Oncology Clinic
    Athens, 14564, Greece
  • General Hospital of Thessaloniki "G. Papanikolaou", Pulmonary Clinic, Aristotle University of Thessaloniki
    Thessaloniki, 57010, Greece
  • Országos Korányi TBC és Pulmonológiai Intézet, 6. Pulmonológia és Bronchologia
    Budapest, 1121, Hungary
  • Országos Korányi TBC és Pulmonológiai lntézet, 14. Pulmonológia
    Budapest, 1121, Hungary
  • Veszprém Megyei Tüdögyógyintézet, 3. Pulmonológiai Osztály
    Farkasgyepu, 8582, Hungary
  • Mátrai Gyógyintézet, Bronchológia
    Matrahaza, 3233, Hungary
  • Miskolci Semmelweis Kórház és Egyetemi Oktatókórház, Pulmonológiai Osztály
    Miskolc, 3529, Hungary

Showing the first 100 of 160 sites across 20 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Aix SP, Ciuleanu TE, Navarro A, Cousin S, Bonanno L, Smit EF, Chiappori A, Olmedo ME, Horvath I, Grohe C, Farago AF, Lopez-Vilarino JA, Cullell-Young M, Nieto A, Vasco N, Gomez J, Kahatt C, Zeaiter A, Carcereny E, Roubec J, Syrigos K, Lo G, Barneto I, Pope A, Sanchez A, Kattan J, Zarogoulidis K, Waller CF, Bischoff H, Juan-Vidal O, Reinmuth N, Domine M, Paz-Ares L. Combination lurbinectedin and doxorubicin versus physician's choice of chemotherapy in patients with relapsed small-cell lung cancer (ATLANTIS): a multicentre, randomised, open-label, phase 3 trial. Lancet Respir Med. 2023 Jan;11(1):74-86. doi: 10.1016/S2213-2600(22)00309-5. Epub 2022 Oct 14. PubMed 36252599 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Feb 2020, 41 months.

Results were first posted in Oct 2021, 1 year 8 months after primary completion.

Of 55 industry-sponsored phase 3 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 44. This study's 41 months is above that.

Counting every sponsor, half of 68 studies reached it within 41 months; a quarter within 31 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2015
First posted
Oct 2, 2015
StartActual
Aug 30, 2016
Primary completionActual
Feb 24, 2020
CompletionActual
Feb 24, 2020
Results first posted
Oct 28, 2021
Last update
Oct 28, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02566993
Lead sponsor
PharmaMar
Responsible party
Sponsor
First posted
Oct 2, 2015
Start date
Aug 30, 2016
Primary completion
Feb 24, 2020
Completion
Feb 24, 2020
Results posted
Oct 28, 2021
Last update
Oct 28, 2021
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: PM 01183 · Doxorubicin

Start the discussion